BackAmbrx Biopharma Overview

Ambrx Biopharma Long Term Debt

Track Ambrx Biopharma's long-term debt ($8.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$8.61M

Peer average / median

Loading

Ambrx Biopharma Long Term Debt History

Loading

Ambrx Biopharma vs. peers: Long Term Debt Comparison

Loading

Ambrx Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ambrx Biopharma (AMAM) FAQ

As of the most recent data (September 2023), AMAM shows a long-term debt of $8.6M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMAM's long-term debt is now $8.6M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Ambrx Biopharma is outperforming or lagging.

Tracking AMAM's long-term debt over time shows whether Ambrx Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $8.6M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Ambrx Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $8.6M) with ownership activity and broader fundamentals.

Ambrx Biopharma's long-term debt is $8.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.